Evaluation of skeletal muscle metabolism and response to erythropoietin treatment in patients with chronic renal failure using 99Tcm-sestamibi leg scintigraphy

Basit Öğe Kaydı
dc.authoridCermik, Tevfik Fikret/0000-0001-7622-7277
dc.authorwosidCermik, Tevfik Fikret/A-9694-2018
dc.contributor.authorSarikaya, A
dc.contributor.authorSen, S
dc.contributor.authorÇermik, TF
dc.contributor.authorBirtane, M
dc.contributor.authorBerkarda, S
dc.date.accessioned2024-06-12T11:19:47Z
dc.date.available2024-06-12T11:19:47Z
dc.date.issued2000
dc.departmentTrakya Üniversitesien_US
dc.description.abstractIt is well known that uraemia affects skeletal muscle metabolism. This has been attributed to a variety of causes, including anaemia, vitamin D, carnitine deficiency and hyperparathyroidism. The aim of this study was to ascertain whether Tc-99(m)-sestamibi leg scintigraphy is useful in the evaluation of skeletal muscle metabolism and the monitoring of treatment response in uraemic myopathy. Forty patients with chronic renal failure and 24 normal controls underwent examination. Fifteen patients with chronic renal failure received erythropoietin treatment. Tc-99(m)-sestamibi leg scintigraphy was performed in all subjects and in 15 patients after therapy. The calf-to-ankle uptake ratio was calculated by semi-quantitative analysis and normalized to lean body mass. The normalized uptake ratios were significantly different between patients and controls. After erythropoietin therapy, there was a significant increase in the normalized uptake ratios compared with pre-therapy. Our results suggest that Tc-99(m)-sestamibi leg scintigraphy is useful in the assessment of muscle metabolic abnormalities and the effect of treatment in uraemic myopathy. ((C) 2000 Lippincott Williams & Wilkins).en_US
dc.identifier.doi10.1097/00006231-200001000-00014
dc.identifier.endpage87en_US
dc.identifier.issn0143-3636
dc.identifier.issue1en_US
dc.identifier.pmid10717907en_US
dc.identifier.scopus2-s2.0-0033629176en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage83en_US
dc.identifier.urihttps://doi.org/10.1097/00006231-200001000-00014
dc.identifier.urihttps://hdl.handle.net/20.500.14551/25342
dc.identifier.volume21en_US
dc.identifier.wosWOS:000085171400012en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherLippincott Williams & Wilkinsen_US
dc.relation.ispartofNuclear Medicine Communicationsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectRecombinant-Human-Erythropoietinen_US
dc.subjectStandardized Uptake Valuesen_US
dc.subjectHemodialysis-Patientsen_US
dc.subjectParathyroid-Hormoneen_US
dc.subjectExercise Capacityen_US
dc.subjectVitamin-Den_US
dc.subjectAnemiaen_US
dc.subjectIsonitrileen_US
dc.subjectDiseaseen_US
dc.subjectTl-201en_US
dc.titleEvaluation of skeletal muscle metabolism and response to erythropoietin treatment in patients with chronic renal failure using 99Tcm-sestamibi leg scintigraphyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu